CompletedPHASE1, PHASE2NCT00005803
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Studying B-cell prolymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- David MaloneyFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Intervention
- Autologous Hematopoietic Stem Cell Transplantation(procedure)
- Enrollment
- 76 enrolled
- Eligibility
- 75 years · All sexes
- Timeline
- 1999 – 2018
Study locations (5)
- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
- LDS Hospital, Salt Lake City, Utah, United States
- VA Puget Sound Health Care System, Seattle, Washington, United States
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
- Universitaet Leipzig, Leipzig, Germany
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005803 on ClinicalTrials.govOther trials for B-cell prolymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05418088Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesSumithira Vasu
- ACTIVE NOT RECRUITINGPHASE1NCT02153580Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaCity of Hope Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT02007044Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT01589302PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic LeukemiaKami Maddocks, MD